Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study.

A, Karasik; S, Lanzinger; Tan E, Chia-Hui; D, Yabe; DJ, Kim; WH, Sheu; C, Melzer-Cohen; RW, Holl; KH, Ha; K, Khunti; F, Zaccardi; A, Subramanian; K, Nirantharakumar; T, Nyström; L, Niskanen; Jensen M, Linnemann; F, Hoti; R, Klement; A, Déruaz-Luyet; MH, Kyaw; L, Koeneman; D, Vistisen; B, Carstensen; S, Halvorsen; G, Langslet; Farsani S, Fazeli; E, Patorno; J, Núñez

doi:10.1016/j.diabet.2022.101418

Public

Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study.

Shared by NobleBlocks on Jan 3, 2023 • 12:00 AM UTC

Authors:

Karasik A

Lanzinger S

Chia-Hui Tan E

Abstract

Background Continued expansion of indications for sodium-glucose cotransporter-2 inhibitors increases importance of evaluating cardiovascular and kidney efficacy and safety of empagliflozin in patients with type 2 diabetes compared to similar therapies.Methods The EMPRISE Europe and Asia study is a ...

Subject

Cardiovascular diseases

Meta-analysis

Heart Failure

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!